Macy's, Abercrombie and Moderna fall premarket; Sage soars

Investing.com -- US stock futures fell Monday, as investors fretted that the hot jobs report will prompt the Federal Reserve to hold back on rate cuts this year.

Here are some of the biggest premarket US stock movers today: Macy’s (NYSE:M ) stock fell 3.4% after the retailer said it expects fourth-quarter net sales to be slightly below the low-end of the previously issued range of $7.8 billion to $8.0 billion. Abercrombie & Fitch (NYSE:ANF ) stock slumped 7.2% despite the retailer lifting its annual net sales growth target for the current quarter, with the increase not enough to reassure investors the company could keep up the recent growth rate. Moderna (NASDAQ:MRNA ) stock plummeted 16% after the drugmaker cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus shot and weak demand for COVID-19 vaccines. Sage Therapeutics (NASDAQ:SAGE ) stock gained 36% after the company confirmed that biotech major Biogen (NASDAQ:BIIB ), down 0.1%, has made a nonbinding proposal to acquire all of the outstanding shares it doesn’t already own. Apple (NASDAQ:AAPL ) stock fell 0.9% as the tech giant faces a mass lawsuit brought on behalf of around 20 million iPhone and iPad users in the UK, who were allegedly overcharged for app purchases. Lululemon (NASDAQ:LULU ) stock rose 3.9% after the sportswear maker raised its current-quarter targets, benefiting from a bump in demand for its apparel during the holiday season. Enfusion (NYSE:ENFN ) stock soared 12% after Clearwater Analytics (NYSE:CWAN ), up 1.7%, agreed to acquire the investment management platform in a $1.5 billion cash-and-stock deal. Intracellular (NASDAQ:ITCI ) stock soared 35% after Johnson & Johnson (NYSE:JNJ ), up 0.3%, said it would buy the drugmaker for about $14.6 billion, boosting its presence in the market for neurological disorder treatments. Air Lease (NYSE:AL ) stock fell 2% after the aircraft lessor said delays in deliveries from major aircraft manufacturers were in some cases getting worse, and estimates of delay time could not be trusted.

Source: Investing.com